Intermittent Dosing with Sulindac Provides Effective Colorectal Cancer Chemoprevention in the Azoxymethane-Treated Mouse Model
- 1 August 2017
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 10 (8) , 459-466
Abstract
Sulindac is an NSAID that can provide effective chemoprevention for colorectal cancer. In this study, alternative dosing regimens of sulindac were evaluated for their chemoprevention effectiveness in the azoxymethane-treated A/J mouse model of colorectal cancer. High-resolution endoscopic optical coherence tomography was utilized to time-serially measure tumor number and tumor burden in the distal colon as the biological endpoints. Four treatment groups were studied: (i) daily for 20 weeks (sulindac-daily); (ii) for 2 weeks, then no sulindac for 2 weeks, cycle repeated 5 times (sulindac-2); (iii) for 10 weeks (“on”), then no sulindac for 10 weeks (“off”; sulindac-10); and (iv) no sulindac (sulindac-none). Sulindac-2 and sulindac-daily had statistically significantly lower final tumor counts and slopes (change in number of tumors per week) when compared with sulindac-none (P < 0.0001). All of the treatment groups had statistically significantly lower final tumor burdens and slopes when compared with sulindac-none (P < 0.001). There was a prolonged latency period in the sulindac-10 group, with no significant difference between the “off” portion of this treatment and sulindac-none. These results suggest that, although daily doses of sulindac provide the most optimal effects, intermittent doses of sulindac in a 50% duty cycle with an overall 4-week period (sulindac-2 model) can provide highly effective chemoprevention of colorectal cancer in this model. After cessation of sulindac treatment (sulindac-10 “off”), there is no evidence of either a persistent chemopreventive effect or a rebound effect. Cancer Prev Res; 10(8); 459–66. ©2017 AACR.Keywords
All Related Versions
This publication has 28 references indexed in Scilit:
- Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancerExpert Review of Gastroenterology & Hepatology, 2012
- An intermittent approach for cancer chemopreventionNature Reviews Cancer, 2011
- Of Timing and Surrogates: A Way Forward for Cancer ChemopreventionClinical Cancer Research, 2011
- Current concepts in colorectal cancer preventionExpert Review of Gastroenterology & Hepatology, 2009
- Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib TrialCancer Prevention Research, 2009
- Risk of Cardiovascular Events in a Randomized Placebo-Controlled, Double-Blind Trial of Difluoromethylornithine plus Sulindac for the Prevention of Sporadic Colorectal AdenomasCancer Prevention Research, 2009
- Combination Chemoprevention of Intestinal Carcinogenesis in a Murine Model of Familial Adenomatous PolyposisNutrition and Cancer, 2008
- Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind TrialCancer Prevention Research, 2008
- Serial endoscopy in azoxymethane treated mice using ultra-high resolution optical coherence tomographyCancer Biology & Therapy, 2007
- The Selective Estrogen Receptor Modulator Arzoxifene and the Rexinoid LG100268 Cooperate to Promote Transforming Growth Factor β-Dependent Apoptosis in Breast CancerCancer Research, 2004